

For Immediate Release

TSX Exchange Symbol: **RVX****Resverlogix is Presenting at IAS HDL Workshop***Novel ApoA-I/HDL raising drug, RVX-208, to be featured in oral presentation*

Calgary, AB, October 11, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce that tomorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled “A novel drug that raises apolipoprotein A-I and HDL *in vitro* and *in vivo*” will be presented by Dr. Norman Wong, Resverlogix Co-Founder and Chairman of the Scientific Advisory Board on October 12th at the Petros M. Nomikos Conference Center in Santorini, Greece.

“This meeting of the IAS attracts internationally elite scientists in cardiovascular medicine. This venue is ideal for announcing the favorable and novel features of RVX-208, scheduled for clinical trials later this year,” stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. Dr. Johansson added, “RVX-208 is a small molecule for oral administration that has shown to have unprecedented effects in raising ApoA-I and functional HDL. There is an ever-increasing body of evidence from predictive animal models that indicates RVX-208’s potential for preventing and regressing atherosclerosis. We are very happy to participate in this important conference.”

Mr. Donald McCaffrey, President and CEO of Resverlogix said, “These highly regarded researchers who will be participating at the event clearly understand that there is a large unmet medical need in cardiovascular disease (CVD). There is a lot of excitement among these key opinion leaders that Resverlogix’s novel small molecule drug could address many of the shortcomings of current CVD drugs.”

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Sarah Zapotichny
Manager, Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Sarah@resverlogix.com

Website: www.resverlogix.com